Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tocilizumab in Polymyalgia Rheumatica (SEMAPHORE)
NCT02908217Phase 3Completed
- Sponsor
- Centre Hospitalier Universitaire de Brest
- Start
- Feb 2017
- Primary completion
- Nov 2020
- Modality
- Antibody Conjugates, Recombinant Proteins and Enzymes, Engineered Antibody Formats
- Countries
- 1
01
Overview
A Phase 3 trial of tocilizumab in polymyalgia rheumatica (PMR), sponsored by Centre Hospitalier Universitaire de Brest. Started Feb 2017; status: completed.
02
Drugs
tocilizumab
03
Conditions
polymyalgia rheumatica (PMR)
Beyond the preview
Go deeper on NCT02908217.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02908217.